A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.136 · Cited by 3,060 · see citing works

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,542 · see citing works

Chimeric Antigen Receptor Therapy

June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,355 · see citing works

Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy

Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512 · see citing works

First-Line Nivolumab plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (CheckMate 743): A Multicentre, Randomised, Open-Label, Phase 3 Trial

Baas, P., Scherpereel, A., Nowak, A. K., Fujimoto, N., Peters, S., Tsao, A. S., Mansfield, A. S., Popat, S., Jahan, T., Antonia, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32714-8 · Cited by 1,215 · see citing works

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

Cherkassky, L., Morello, A., Villena‐Vargas, J., Feng, Y., Dimitrov, D. S., Jones, D. R., Sadelain, M., & Adusumilli, P. S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83092 · Cited by 1,075 · see citing works

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

Maher, J. F., Brentjens, R. J., Gunset, G., Rivière, I., & Sadelain, M. (2002) · Nature Biotechnology · doi:10.1038/nbt0102-70 · Cited by 1,038 · see citing works

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial

Zalcman, G., Mazieres, J., Margery, J., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., Molinier, O., Corre, R., Monnet, I., Gounant, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01238-6 · Cited by 968 · see citing works

Clinical manufacturing of CAR T cells: foundation of a promising therapy

Wang, X., & Rivière, I. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.15 · Cited by 637 · see citing works

Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors

Grosser, R., Cherkassky, L., Chintala, N., & Adusumilli, P. S. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.006 · Cited by 603 · see citing works

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity

Adusumilli, P. S., Cherkassky, L., Villena‐Vargas, J., Colovos, C., Servais, E. L., Plotkin, J., Jones, D. R., & Sadelain, M. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3010162 · Cited by 572 · see citing works

PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers

Yarchoan, M. M., Albacker, L. A., Hopkins, A. C., Montesion, M., Murugesan, K., Vithayathil, T., Zaidi, N., Azad, N. S., Laheru, D. A., Frampton, G. M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126908 · Cited by 554 · see citing works

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy

Carbone, M., Adusumilli, P. S., Alexander, H. R., Baas, P., Bardelli, F., Bononi, A., Bueno, R., Felley‐Bosco, E., Galateau-Sallé, F., Jablons, D. M., et al. (2019) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21572 · Cited by 454 · see citing works

Mesothelin-Targeted CARs: Driving T cells to Solid Tumors

Morello, A., Sadelain, M., & Adusumilli, P. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0583 · Cited by 420 · see citing works

Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells.

Rivière, I., Brose, K., & Mulligan, R. C. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.6733 · Cited by 375 · see citing works

Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy

Hollyman, D., Stefanski, J., Przybylowski, M., Bartido, S. M., Bórquez-Ojeda, O., Taylor, C., Yeh, R., Capacio, V., Olszewska, M., Hosey, J., et al. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318194a6e8 · Cited by 316 · see citing works

Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy

Pastan, I. H., & Hassan, R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0337 · Cited by 252 · see citing works

Chimeric antigen receptor T-cell therapy for solid tumors

Newick, K., Moon, E. K., & Albelda, S. Μ. (2016) · Molecular Therapy — Oncolytics · doi:10.1038/mto.2016.6 · Cited by 237 · see citing works

Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center

Flores, R. M., Zakowski, M. F., Venkatraman, E. S., Krug, L. M., Rosenzweig, K. E., Dycoco, J., Lee, C., Yeoh, C. B., Bains, M. S., & Rusch, V. W. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31815608d9 · Cited by 226 · see citing works

Mesothelin Overexpression Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Epithelioid Pleural Mesothelioma Patients

Servais, E. L., Colovos, C., Rodríguez, L., Bograd, A. J., Nitadori, J., Sima, C. S., Rusch, V. W., Sadelain, M., & Adusumilli, P. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2614 · Cited by 198 · see citing works

Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma

Kachala, S. S., Bograd, A. J., Villena‐Vargas, J., Suzuki, K., Servais, E. L., Kadota, K., Chou, J. F., Sima, C. S., Vertes, E. L., Rusch, V. W., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1862 · Cited by 181 · see citing works

Driving CARs on the uneven road of antigen heterogeneity in solid tumors

Chen, N., Li, X., Chintala, N. K., Tano, Z. E., & Adusumilli, P. S. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.002 · Cited by 143 · see citing works

Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1)

Armato, S. G., & Nowak, A. K. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.034 · Cited by 140 · see citing works

The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers

Ujiie, H., Kadota, K., Nitadori, J., Aerts, J. G. J. V., Woo, K. M., Sima, C. S., Travis, W. D., Jones, D. R., Krug, L. M., & Adusumilli, P. S. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1009285 · Cited by 135 · see citing works

Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation

Tsao, A. S., Lindwasser, O. W., Adjei, A. A., Adusumilli, P. S., Beyers, M., Blumenthal, G. M., Bueno, R., Burt, B. M., Carbone, M., Dahlberg, S. E., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.2036 · Cited by 121 · see citing works

Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-Like Phenotype, Distant Metastases and Decreased Survival

Tozbikian, G., Brogi, E., Kadota, K., Catalano, J. P., Akram, M. M., Patil, S., Ho, A., Reis-Filho, J., Weigelt, B., Norton, L., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114900 · Cited by 97 · see citing works

High mesothelin expression in advanced lung adenocarcinoma is associated withKRASmutations and a poor prognosis

Thomas, A., Chen, Y., Steinberg, S. M., Luo, J., Pack, S., Raffeld, M. A., Abdullaev, Z., Alewine, C., Rajan, A., Giaccone, G., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3429 · Cited by 84 · see citing works

Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies

Kiesgen, S., Chicaybam, L., Chintala, N. K., & Adusumilli, P. S. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.10.001 · Cited by 82 · see citing works

Cytotoxic T Cells in PD-L1–Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors

Awad, M. M., Jones, R. E., Liu, H., Lizotte, P. H., Ivanova, E. V., Kulkarni, M. M., Herter-Sprie, G. S., Liao, X., Santos, A. A., Bittinger, M. A., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0171 · Cited by 74 · see citing works

The internal ribosomal entry site of the encephalomyocarditis virus enables reliable coexpression of two transgenes in human primary T lymphocytes

Gallardo, H., Tan, C. W., & Sadelain, M. (1997) · Gene Therapy · doi:10.1038/sj.gt.3300506 · Cited by 69 · see citing works

A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity

Feng, Y., Xiao, X., Zhu, Z., Streaker, E. D., Ho, M., Pastan, I. H., & Dimitrov, D. S. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0945 · Cited by 62 · see citing works

Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?

Cantini, L., Hassan, R., Sterman, D. H., & Aerts, J. G. J. V. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00343 · Cited by 59 · see citing works

Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma

Bograd, A. J., Suzuki, K., Vertes, E. L., Colovos, C., Morales, E. A., Sadelain, M., & Adusumilli, P. S. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1103-6 · Cited by 51 · see citing works

Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes

Klampatsa, A., O’Brien, S., Thompson, J. C., Rao, A. S., Stadanlick, J. E., Martinez, M. C., Liousia, M., Cantu, E., Cengel, K. A., Moon, E. K., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1638211 · Cited by 48 · see citing works

Tissue and Serum Mesothelin Are Potential Markers of Neoplastic Progression in Barrett's Associated Esophageal Adenocarcinoma

Rizk, N. P., Servais, E. L., Tang, L. H., Sima, C. S., Gerdes, H., Fleisher, M., Rusch, V. W., & Adusumilli, P. S. (2012) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-0993 · Cited by 40 · see citing works

Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1

Eguchi, T., Kadota, K., Mayor, M., Zauderer, M. G., Rimner, A., Rusch, V. W., Travis, W. D., Sadelain, M., & Adusumilli, P. S. (2017) · Oncotarget · doi:10.18632/oncotarget.20845 · Cited by 34 · see citing works

18F-Fluorodeoxyglucose PET/CT and dynamic contrast-enhanced MRI as imaging biomarkers in malignant pleural mesothelioma

Hall, D. O., Hooper, C. E., Searle, J., Darby, M. J., White, P., Harvey, J., Braybrooke, J. P., Maskell, N. A., Masani, V., & Lyburn, I. D. (2018) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000789 · Cited by 12 · see citing works

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · see citing works

Clinical implications of T cell exhaustion for cancer immunotherapy

Chow, A., Perica, K., Klebanoff, C. A., & Wolchok, J. D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00689-z · Cited by 1,044 · see citing works

CAR immune cells: design principles, resistance and the next generation

Labanieh, L., & Mackall, C. L. (2023) · Nature · doi:10.1038/s41586-023-05707-3 · Cited by 673 · see citing works

Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours

Flugel, C. L., Majzner, R. G., Krenciute, G., Dotti, G., Riddell, S. R., Wagner, D. L., & Abou‐El‐Enein, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00704-3 · Cited by 571 · see citing works

PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial

Narayan, V., Barber-Rotenberg, J. S., Jung, I.-Y., Lacey, S. F., Rech, A. J., Suhoski, M. M., Hwang, W., Lal, P., Carpenter, E. L., Maude, S. L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01726-1 · Cited by 548 · see citing works

CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn

Albelda, S. Μ. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00832-4 · Cited by 535 · see citing works

Immunotherapy: Reshape the Tumor Immune Microenvironment

Bingzhe, L. V., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844142 · Cited by 489 · see citing works

CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors

Peng, L., Sferruzza, G., Yang, L., Zhou, L., & Chen, S. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01207-0 · Cited by 416 · see citing works

Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion

Gumber, D., & Wang, L. D. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103941 · Cited by 409 · see citing works

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals

Philipp, N., Pasikhani, M. K., Nicholls, A., Vick, B., Wulf, J., Straub, T., Scheurer, M., Muth, A., Hänel, G., Nixdorf, D., et al. (2022) · Blood · doi:10.1182/blood.2022015956 · Cited by 285 · see citing works

Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier

Vafaei, S., Zekiy, A. O., Khanamir, R. A., Zaman, B. A., Ghayourvahdat, A., Azimizonuzi, H., & Zamani, M. (2022) · Cancer Cell International · doi:10.1186/s12935-021-02407-8 · Cited by 278 · see citing works

Engineered cellular immunotherapies in cancer and beyond

Finck, A., Blanchard, T., Roselle, C., Golinelli, G., & June, C. (2022) · Nature Medicine · doi:10.1038/s41591-022-01765-8 · Cited by 240 · see citing works

Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors

Sloas, D. C., Gill, S. I., & Klichinsky, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.783305 · Cited by 240 · see citing works

Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas

Monje, M., Mahdi, J., Majzner, R. G., Yeom, K. W., Schultz, L. M., Richards, R. M., Barsan, V. V., Song, K.-W., Kamens, J. L., Baggott, C., et al. (2024) · Nature · doi:10.1038/s41586-024-08171-9 · Cited by 239 · see citing works

CAR-T: What Is Next?

Chen, Y., Abila, B., & Kamel, Y. M. (2023) · Cancers · doi:10.3390/cancers15030663 · Cited by 235 · see citing works

Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results

Qi, C., Liu, C., Gong, J., Liu, D., Wang, X., Zhang, P., Qin, Y., Ge, S., Zhang, M., Peng, Z., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03037-z · Cited by 235 · see citing works

The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies

Sorkhabi, A. D., Khosroshahi, L. M., Sarkesh, A., Mardi, A., Aghebati‐Maleki, A., Maleki, L. A., & Baradaran, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1113882 · Cited by 215 · see citing works

Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021

Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01362-9 · Cited by 202 · see citing works

Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial

Bagley, S. J., Binder, Z. A., Lamrani, L., Marinari, E., Desai, A. S., Nasrallah, M. P., Maloney, E., Brem, S. S., Lustig, R. A., Kurtz, G. A., et al. (2024) · Nature Cancer · doi:10.1038/s43018-023-00709-6 · Cited by 199 · see citing works

Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells

Agarwal, S., Aznar, M. A., Rech, A. J., Good, C. R., Kuramitsu, S., Da, T., Gohil, M., Chen, L., Hong, S.-J. A., Ravikumar, P., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.001 · Cited by 189 · see citing works

Next-Generation CAR T-cell Therapies

Young, R. M., Engel, N. W., Uslu, U., Wellhausen, N., & June, C. H. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1683 · Cited by 182 · see citing works

Beyond the blood: expanding CAR T cell therapy to solid tumors

Uslu, U., & June, C. H. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02446-2 · Cited by 170 · see citing works

Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors

Chen, T. R., Wang, M., Chen, Y., & Liu, Y. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03315-3 · Cited by 157 · see citing works

Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions

Alnefaie, A., Albogami, S. M., Asiri, Y. A., Ahmad, T., Alotaibi, S. S., Al-Sanea, M. M., & Althobaiti, H. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.797440 · Cited by 153 · see citing works

Exhaustion of CAR T cells: potential causes and solutions

Kouro, T., Himuro, H., & Sasada, T. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03442-3 · Cited by 151 · see citing works

PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial

Dorff, T. B., Blanchard, M. S., Adkins, L. N., Luebbert, L., Leggett, N. A., Shishido, S. N., Macias, A., Real, M. M. D., Dhapola, G., Egelston, C. A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02979-8 · Cited by 144 · see citing works

Development of therapeutic antibodies for the treatment of diseases

Wang, Z., Wang, G., Lu, H., Li, H., Tang, M., & Tong, A. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00100-4 · Cited by 136 · see citing works

Current trends in sensitizing immune checkpoint inhibitors for cancer treatment

Wei, J., Li, W., Zhang, P., Guo, F., & Liu, M. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02179-5 · Cited by 134 · see citing works

CAR T cell therapy in solid tumors: A review of current clinical trials

Patel, U., Abernathy, J., Savani, B. N., Oluwole, O. O., Sengsayadeth, S. M., & Dholaria, B. (2021) · eJHaem · doi:10.1002/jha2.356 · Cited by 133 · see citing works

CAR T cell combination therapies to treat cancer

Uslu, U., Castelli, S., & June, C. H. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.07.002 · Cited by 129 · see citing works

PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages

Yamaguchi, Y., Gibson, J., Ou, K., Lopez, L. S., Ng, R. H., Leggett, N. A., Jönsson, V. D., Zarif, J. C., Lee, P. P., Wang, X., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004400 · Cited by 128 · see citing works

Advancing CAR T cell therapy through the use of multidimensional omics data

Yang, J., Chen, Y., Jing, Y., Green, M. R., & Han, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00729-2 · Cited by 128 · see citing works

Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma

Wehrli, M., Guinn, S. R., Birocchi, F., Kuo, A., Sun, Y., Larson, R. C., Almazan, A. J., Scarfò, I., Bouffard, A. A., Bailey, S. R., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3841 · Cited by 127 · see citing works

Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach

Ghisoni, E., Morotti, M., Sarivalasis, A., Grimm, A. J., Kandalaft, L. E., Laniti, D. D., & Coukos, G. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00937-4 · Cited by 123 · see citing works

Immune checkpoint inhibitors: breakthroughs in cancer treatment

Kong, X., Zhang, J., Chen, S., Wang, X., Xi, Q., Shen, H., & Zhang, R. (2024) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2024.0055 · Cited by 122 · see citing works

Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia

Gottschlich, A., Thomas, M., Grünmeier, R., Lesch, S., Rohrbacher, L., Igl, V., Briukhovetska, D., Benmebarek, M.-R., Vick, B., Dede, S., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01684-0 · Cited by 121 · see citing works

Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting

Lee, E. H. J., Murad, J. P., Christian, L., Gibson, J., Yamaguchi, Y., Cullen, C., Gumber, D., Park, A. K., Young, C. A., Monroy, I., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40115-1 · Cited by 118 · see citing works

Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results

Hassan, R., Butler, M. O., O'Cearbhaill, R. E., Oh, D. Y., Johnson, M. L., Zikaras, K., Smalley, M., Ross, M. G., Tanyi, J. L., Ghafoor, A., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02452-y · Cited by 117 · see citing works

Adoptive cell therapy for cancer treatment

Du, S., Yan, J., Xue, Y., Zhong, Y., & Dong, Y. (2023) · Exploration · doi:10.1002/exp.20210058 · Cited by 114 · see citing works

Engineered T cell therapy for viral and non-viral epithelial cancers

Norberg, S. M., & Hinrichs, C. S. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.10.016 · Cited by 107 · see citing works

T STEM -like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models

Meyran, D., Zhu, J. J., Butler, J., Tantalo, D. G. M., Macdonald, S., Nguyen, T. N., Wang, M., Thio, N., D’Souza, C., Qin, V. M., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abk1900 · Cited by 107 · see citing works

The affinity of antigen-binding domain on the antitumor efficacy of CAR T cells: Moderate is better

Mao, R., Kong, W., & He, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1032403 · Cited by 105 · see citing works

Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology

Tao, R., Han, X., Bai, X., Yu, J., Ma, Y.-W., Chen, W., Zhang, D., & Li, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1354825 · Cited by 105 · see citing works

CAR-T cells in solid tumors: Challenges and breakthroughs

Escobar, G., Berger, T. R., & Maus, M. V. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102353 · Cited by 104 · see citing works

Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells

Haas, A. R., Golden, R. J., Litzky, L. A., Engels, B., Zhao, L., Xu, F., Taraszka, J. A., Ramones, M., Granda, B. W., Chang, W., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.06.006 · Cited by 102 · see citing works

3D cancer models: One step closer to in vitro human studies

Manduca, N., Maccafeo, E., Maria, R. D., Sistigu, A., & Musella, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1175503 · Cited by 95 · see citing works

The next generation of immunotherapies for lung cancers

Zhao, S., Zhao, H., Yang, W., & Zhang, L. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01035-9 · Cited by 91 · see citing works

The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells

Li, J., Xiao, Z., Wang, D., Jia, L., Nie, S., Zeng, X., & Hu, W. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01844-5 · Cited by 88 · see citing works

Recent Advances in CAR-Based Solid Tumor Immunotherapy

Shin, M. H., Oh, E., Kim, Y. J., Nam, D.-H., Jeon, S., Yu, J. H., & Minn, D. (2023) · Cells · doi:10.3390/cells12121606 · Cited by 82 · see citing works

CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition

Andreu-Saumell, I., Rodríguez-García, A., Mühlgrabner, V., Giménez-Alejandre, M., Marzal, B., Castellsagué, J., Brasó‐Maristany, F., Calderón, H., Angelats, L., Colell, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47799-z · Cited by 81 · see citing works

Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy

Dabas, P., & Danda, A. (2023) · Medical Oncology · doi:10.1007/s12032-023-02146-y · Cited by 79 · see citing works

Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors

Khan, S. H., Choi, Y., Veena, M. S., Lee, J. K., & Shin, D. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1489827 · Cited by 79 · see citing works

Regional CAR T cell therapy: An ignition key for systemic immunity in solid tumors

Cherkassky, L., Hou, Z., Amador-Molina, A., & Adusumilli, P. S. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.006 · Cited by 77 · see citing works

A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021

Miao, L., Zhang, J., Zhang, Z., Wang, S., Tang, F., Teng, M., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.840956 · Cited by 75 · see citing works

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

Zheng, Z., Li, S., Liu, M., Chen, C., Zhang, L., & Zhou, D. (2023) · Cancers · doi:10.3390/cancers15133476 · Cited by 72 · see citing works

Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors

Chen, Q., Lu, L., & Ma, W. (2022) · Cancers · doi:10.3390/cancers14235983 · Cited by 72 · see citing works

PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion

Ouyang, W., Jin, S., Xu, N., Liu, W.-Y., Zhao, H. Q., Zhang, L., Kang, L., Tao, Y., Liu, Y., Wang, Y., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008429 · Cited by 70 · see citing works

Preclinical Evaluation of CAR T Cell Function: In Vitro and In Vivo Models

Si, X., Xiao, L., Brown, C. E., & Wang, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063154 · Cited by 69 · see citing works

Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in-human phase I study

Hu, Y., Zu, C., Zhang, M., Wei, G., Li, W., Fu, S., Hong, R., Zhou, L., Wu, W., Cui, J., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102010 · Cited by 67 · see citing works

Locoregional delivery of CAR-T cells in the clinic

Sagnella, S. M., White, A. L., Yeo, D., Saxena, P., van Zandwijk, N., & Rasko, J. E. J. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106329 · Cited by 62 · see citing works

Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy

Almawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 63 · see citing works

Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy

Das, S., Valton, J., Duchateau, P. N., & Poirot, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1172681 · Cited by 61 · see citing works

Prospects and challenges of CAR-T cell therapy combined with ICIs

Lv, Y., Luo, X., Xie, Z., Qiu, J.-Y., Yang, J., Deng, Y., Long, R., Tang, G., Zhang, C., & Zuo, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1368732 · Cited by 61 · see citing works

Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential

Wang, X., Yang, X., Yuan, X., Wang, W., & Wang, Y. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00341-7 · Cited by 60 · see citing works

Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models

Schoutrop, E., Poiret, T., Serafi, I. E., Zhao, Y. H., He, R., Moter, A., Henriksson, J., Hassan, M., Magalhaes, I., & Mattsson, J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005691 · Cited by 60 · see citing works

Developments in targeted therapy & immunotherapy—how non-small cell lung cancer management will change in the next decade: a narrative review

Li, M. S. C., Mok, K. K. S., & Mok, T. S. K. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-4444 · Cited by 60 · see citing works

CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes

Jilani, S., Saco, J. D., Mugarza, E., Pujol-Morcillo, A., Chokry, J., Ng, C., Abril-Rodríguez, G., Berger-Manerio, D., Pant, A., Hu, J. G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45221-2 · Cited by 60 · see citing works

Oncolytic virus and CAR-T cell therapy in solid tumors

Ponterio, E., Haas, T. L., & Maria, R. D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1455163 · Cited by 59 · see citing works

Challenges of Anti-Mesothelin CAR-T-Cell Therapy

Zhai, X., Mao, L., Wu, M., Liu, J., & Yu, S. (2023) · Cancers · doi:10.3390/cancers15051357 · Cited by 58 · see citing works

The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors

Wang, L., Zhang, L., Dunmall, L. C., Wang, Y. Y., Fan, Z., Cheng, Z., & Wang, Y. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216871 · Cited by 58 · see citing works

Future perspectives on engineered T cells for cancer

Posey, A. D., Young, R. M., & June, C. H. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.05.007 · Cited by 58 · see citing works

Immunotherapy approaches for malignant pleural mesothelioma

Fennell, D. A., Dulloo, S., & Harber, J. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00649-7 · Cited by 57 · see citing works

Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors

Ghaedrahmati, F., Esmaeil, N., & Abbaspour, M. (2022) · 癌症：英文版 · doi:10.1002/cac2.12394 · Cited by 57 · see citing works

Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives

Azeez, S. S., Yashooa, R. K., Smail, S. W., Salihi, A. B., Ali, A. S., Mamand, S., & Janson, C. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02386-8 · Cited by 57 · see citing works

Components, Formulations, Deliveries, and Combinations of Tumor Vaccines

Liu, T., Yao, W., Sun, W., Yuan, Y., Liu, C., Liu, X., Wang, X., & Jiang, H. (2024) · ACS Nano · doi:10.1021/acsnano.4c05065 · Cited by 56 · see citing works

A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis

Ma, Q., He, X., Zhang, B., Guo, F., Ou, X., Yang, Q., Shu, P., Chen, Y., Li, K., Gao, G., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01198-2 · Cited by 55 · see citing works

Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin

Liu, X., Onda, M., Watson, N., Hassan, R., Ho, M., Bera, T. K., Wei, J., Chakraborty, A., Beers, R., Zhou, Q., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2202439119 · Cited by 54 · see citing works

Genetically engineered cellular nanoparticles for biomedical applications

Krishnan, N., Peng, F.-X., Mohapatra, A., Fang, R. H., & Zhang, L. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122065 · Cited by 54 · see citing works

Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

Vo, M.-C., Tran, V.-D.-H., Nguyen, V., Ruzimurodov, N., Trung, D. T., Kim, S. K., Jung, S., & Lee, J. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01744-9 · Cited by 55 · see citing works

Immunosenescence, inflammaging, and cancer immunotherapy efficacy

Rodriguez, J. E., Naigeon, M., Goldschmidt, V., Dugage, M. R., Seknazi, L., Danlos, F., Champiat, S., Marabelle, A., Michot, J., Massard, C., et al. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2098718 · Cited by 53 · see citing works

NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development

Dezfouli, A. B., Yazdi, M., Pockley, A. G., Khosravi, M., Kobold, S., Wagner, E., & Multhoff, G. (2021) · Cells · doi:10.3390/cells10123390 · Cited by 51 · see citing works

Adoptive Cell Therapy for Nonhematologic Solid Tumors

Olson, D. J., & Odunsi, K. O. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01618 · Cited by 51 · see citing works

Akkermansia muciniphila: a potential booster to improve the effectiveness of cancer immunotherapy

Fan, S., Jiang, Z., Zhang, Z., Xing, J., Wang, D., & Tang, D. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05199-8 · Cited by 50 · see citing works

Recent advances and remaining challenges in lung cancer therapy

Barr, T., Ma, S., Li, Z., & Yu, J. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002991 · Cited by 50 · see citing works

Intratumoral Injection of Immunotherapeutics: State of the Art and Future Directions

Sheth, R. A., Wehrenberg-Klee, E. P., Patel, S. P., Brock, K. K., Fotiadis, N., & de Baère, T. (2024) · Radiology · doi:10.1148/radiol.232654 · Cited by 50 · see citing works

Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors

Tomar, S., Zhang, J., Khanal, M., Hong, J., Venugopalan, A. K., Jiang, Q., Sengupta, M., Miettinen, M., Li, N., Pastan, I. H., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0073 · Cited by 50 · see citing works

Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma

Yang, C., You, J., Pan, Q., Tang, Y., Cai, L., Huang, Y., Gu, J., Wang, Y., Yang, X., Du, Y., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-03016-0 · Cited by 48 · see citing works

Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers

Gu, X., Zhang, Y., Zhou, W., Wang, F., Yan, F., Gao, H., & Wang, W. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00542-2 · Cited by 47 · see citing works

ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights

Ali, A. M., & DiPersio, J. F. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1432799 · Cited by 47 · see citing works

Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy

Harber, J., Kamata, T., Pritchard, C. A., & Fennell, D. A. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003032 · Cited by 47 · see citing works

A minimally designed PD-L1-targeted nanocomposite for positive feedback-based multimodal cancer therapy

Mei, Y., Tang, L., Zhang, L., Hu, J., Zhang, Z., He, S., Zang, J., & Wang, W. (2022) · Materials Today · doi:10.1016/j.mattod.2022.09.009 · Cited by 46 · see citing works

mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy

Olivera, I., Bolaños, E., González-Gomariz, J., Hervás‐Stubbs, S., Mariño, K. V., Luri‐Rey, C., Etxeberría, I., Cirella, A., Egea, J., Glez‐Vaz, J., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100978 · Cited by 46 · see citing works

CAR-macrophage versus CAR-T for solid tumors: The race between a rising star and a superstar

Chen, K., Liu, M., Wang, J., & Fang, S. (2023) · Biomolecules and Biomedicine · doi:10.17305/bb.2023.9675 · Cited by 46 · see citing works

Modular chimeric cytokine receptors with leucine zippers enhance the antitumour activity of CAR T cells via JAK/STAT signalling

Bell, M. R., Lange, S., Sejdiu, B. I., Ibañez-Vega, J., Shi, H., Sun, X., Meng, X., Nguyen, P., Sutton, M. T., Wagner, J., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01143-w · Cited by 45 · see citing works

Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality

Schoutrop, E., Renken, S., Nilsson, I. M., Hahn, P., Poiret, T., Kiessling, R. W., Wickström, S. L., Mattsson, J., & Magalhaes, I. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2093426 · Cited by 43 · see citing works

CRISPR-Cas System: The Current and Emerging Translational Landscape

Bhokisham, N., Laudermilch, E., Traeger, L. L., Bonilla, T. D., Ruíz-Estévez, M., & Becker, J. R. (2023) · Cells · doi:10.3390/cells12081103 · Cited by 43 · see citing works

Targeting pathogenic CD8+ tissue-resident T cells with chimeric antigen receptor therapy in murine autoimmune cholangitis

Zhu, H., Yang, S.-H., Gao, C., Bian, Z.-H., Chen, X.-M., Huang, R., Meng, Q.-L., Li, X., Jin, H., Tsuneyama, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46654-5 · Cited by 43 · see citing works

Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1/PD-L1 blockade in the clinical spectrum of lung cancer

Li, Y., Sharma, A., & Schmidt‐Wolf, I. G. H. (2024) · Molecular Cancer · doi:10.1186/s12943-023-01926-4 · Cited by 43 · see citing works

Synthetic manipulation of the cancer-immunity cycle: CAR-T cell therapy

Singh, N., & Maus, M. V. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.010 · Cited by 42 · see citing works

Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors

Hong, M., Talluri, S., & Chen, Y. Y. (2023) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2023.103020 · Cited by 42 · see citing works

CAR T cells show promise in mesothelioma

Killock, D. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00547-4 · Cited by 2 · see citing works

Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent.

Adusumilli, P. S., Zauderer, M. G., Rusch, V. W., O'Cearbhaill, R. E., Zhu, A., Ngai, D. A., McGee, E., Chintala, N. K., Messinger, J., Cheema, W., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.2511 · Cited by 93 · see citing works

Abstract CT036: A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy

Adusumilli, P. S., Zauderer, M. G., Rusch, V. W., O'Cearbhaill, R. E., Zhu, A. L., Ngai, D. A., McGee, E., Chintala, N. K., Messinger, J. C., Vincent, A., et al. (2019) · Clinical Trials · doi:10.1158/1538-7445.sabcs18-ct036 · Cited by 9 · see citing works

Phase I clinical safety and preliminary efficacy of PD-1-mesoCAR-T cells in the treatment of malignant pleural/peritoneal mesothelioma.

Xu, Q. L., Liu, Z., Xia, Y., Song, Z., Zhu, Z., Lin, Z., & Wang, S. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.8559 · Cited by 1 · see citing works

The Promise of CAR T-Cell Therapy in Mesothelioma Treatment

Nalley, C. (2021) · Oncology Times · doi:10.1097/01.cot.0000795992.53921.e3